

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 63

Published online August 23, 2021

Online  
Article

IN THIS ISSUE

In Brief: Oritavancin (*Kimyrsa*) for Skin and Skin Structure Infections

### Important Copyright Message

**FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS**

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)  
or call customer service at: 800-211-2769

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 63

Published online August 23, 2021

Online  
Article

### IN THIS ISSUE

In Brief: Oritavancin (*Kimyrza*) for Skin and Skin Structure Infections

### IN BRIEF

## Oritavancin (*Kimyrza*) for Skin and Skin Structure Infections

The FDA has approved *Kimyrza* (Melinta), a new IV formulation of the long-acting lipoglycopeptide antibiotic oritavancin, for treatment of adults with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. *Orbactiv* (Melinta), another IV formulation of oritavancin, was approved in 2014 for the same indication.<sup>1</sup> *Kimyrza* has a smaller infusion volume (250 mL vs 1 L) and a shorter infusion time (1 hour vs 3 hours) compared to *Orbactiv* (see Table 1).

**ACTIVITY** – Oritavancin has demonstrated clinical activity against *Staphylococcus aureus* (including methicillin-resistant strains [MRSA]), *Streptococcus agalactiae*, *Streptococcus anginosus* group, *Streptococcus dysgalactiae*, *Streptococcus pyogenes*, and vancomycin-susceptible isolates of *Enterococcus faecalis*. The drug has been reported to have *in vitro* activity against vancomycin-susceptible and vancomycin-resistant isolates of *Enterococcus faecium*.<sup>2</sup>

**CLINICAL STUDIES** – FDA approval of *Kimyrza* was based on the results of earlier clinical trials with *Orbactiv*<sup>3,4</sup> and one pharmacokinetic study (summarized in the package insert) that showed the two formulations were bioequivalent.

**ADVERSE EFFECTS** – The most common adverse effects of oritavancin are headache, nausea, vomiting, limb and subcutaneous abscess, and diarrhea. Serious hypersensitivity reactions have been reported; in clinical trials, the median onset of hypersensitivity reactions was 1.2 days after administration and the median duration was 2.4 days. Patients with a history of hypersensitivity to another glycopeptide (vancomycin,

Table 1. *Orbactiv* vs *Kimyrza*

	<i>Orbactiv</i>	<i>Kimyrza</i>
Formulation	400 mg lyophilized powder for reconstitution in single-dose vials	1200 mg lyophilized powder for reconstitution in single-dose vials
Dosage	1200 mg IV once	1200 mg IV once
Infusion Time	3 hours	1 hour
Preparation/Diluent	After reconstitution, dilute with D5W only <sup>1</sup> ; final bag volume 1000 mL	After reconstitution, dilute with NS or D5W; final bag volume 250 mL
Contains HPβCD <sup>2</sup>	No	Yes
Cost <sup>3</sup>	\$3077.00	\$4884.00

NS = normal saline; D5W = 5% dextrose in sterile water

- Orbactiv* is not compatible with normal saline. Reconstitution with normal saline may result in precipitation of the drug.
- Hydroxypropyl-β-cyclodextrin (HPβCD) is a solubilizer that is excreted in urine. Its clearance may be reduced in patients with renal impairment; the clinical significance of this reduction is unknown.
- Cost for a single 1200-mg dose. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: Analysource® Monthly, August 5, 2021. Reprinted with permission by First Databank, Inc. All rights reserved. ©2021. www.fdbhealth.com/policies/drug-pricing-policy.

telavancin, or dalbavancin) may be at increased risk. Infusion-related reactions such as pruritus, urticaria, and flushing have also been reported.

**DRUG AND LABORATORY TEST INTERACTIONS** – Oritavancin can interfere with coagulation tests by binding to and preventing the action of commonly used phospholipid reagents; it has no effect on coagulation *in vivo*. Use of IV unfractionated heparin is contraindicated for 120 hours after administration of oritavancin because the drug can falsely elevate activated partial thromboplastin time (aPTT). Oritavancin also artificially prolongs prothrombin time (PT) and INR for up to 12 hours after administration.

Oritavancin is a weak inhibitor of CYP2C9 and 2C19 and a weak inducer of CYP3A4 and 2D6; coadministration with drugs that are primarily metabolized by one of these enzymes can alter their serum concentrations.

**CONCLUSION** – *Kimyrsa*, a new formulation of the long-acting lipoglycopeptide antibiotic oritavancin, has an infusion time of 1 hour and an infusion volume of 250 mL, compared to 3 hours and 1 L with the original formulation (*Orbactiv*). It offers a more convenient option for treatment of adults with acute bacterial skin and skin structure infections, but it is more expensive. ■

1. Oritavancin (Orbactiv) for skin and skin structure infections. *Med Lett Drugs Ther* 2015; 57:3.
2. A Belley et al. Comparative pharmacodynamics of single-dose oritavancin and daily high-dose daptomycin regimens against vancomycin-resistant *Enterococcus faecium* isolates in an *in vitro* pharmacokinetic/pharmacodynamic model of infection. *Antimicrob Agents Chemother* 2017; 61:e01265.
3. GR Corey et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. *N Engl J Med* 2014; 370:2180.
4. GR Corey et al. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. *Clin Infect Dis* 2015; 60:254.

**PRESIDENT:** Mark Abramowicz, M.D.; **VICE PRESIDENT AND EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School  
**VICE PRESIDENT AND EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

**CONTRIBUTING EDITORS:** Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhM, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Franco M. Muggia, M.D., New York University Medical Center; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

**MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS:** Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

**FULFILLMENT AND SYSTEMS MANAGER:** Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli  
**EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS:** Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

#### Subscription Services

**Address:**  
 The Medical Letter, Inc.  
 145 Huguenot St. Ste. 312  
 New Rochelle, NY 10801-7537  
 www.medicalletter.org

**Customer Service:**  
 Call: 800-211-2769 or 914-235-0500  
 Fax: 914-632-1733  
 E-mail: custserv@medicalletter.org

**Permissions:**  
 To reproduce any portion of this issue,  
 please e-mail your request to:  
 permissions@medicalletter.org

**Subscriptions (US):**  
 1 year - \$159; 2 years - \$298;  
 3 years - \$398. \$65 per year  
 for students, interns, residents,  
 and fellows in the US and Canada.  
 Reprints - \$45 per issue or article

**Site License Inquiries:**  
 E-mail: SubQuote@medicalletter.org  
 Call: 800-211-2769  
 Special rates available for bulk  
 subscriptions.

Get Connected:  

Copyright 2021. ISSN 0025-732X

